Pharmacokinetics and effects on thromboxane B2 production following intravenous administration of flunixin meglumine to exercised thoroughbred horses

2015 ◽  
Vol 38 (4) ◽  
pp. 313-320 ◽  
Author(s):  
H. K. Knych ◽  
R. M. Arthur ◽  
D. S. McKemie ◽  
N. Chapman
Keyword(s):  
Intravenous Administration ◽  
Thromboxane B2 ◽  
Flunixin Meglumine ◽  
Thoroughbred Horses

Pharmacokinetics and anti‐inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses

2020 ◽  
Vol 53 (1) ◽  
pp. 102-116
Author(s):  
Heather K. Knych ◽  
Rick M. Arthur ◽  
Daniel S. McKemie ◽  
Russell W. Baden ◽  
Kelsey Seminoff ◽  
...  
Keyword(s):  
Flunixin Meglumine ◽  
Sole Agent ◽  
Thoroughbred Horses ◽  
Anti Inflammatory

Platelet Factor 4 Injection Produces Acute Pulmonary Hypertension in the Awake Lamb 

1995 ◽  
Vol 82 (1) ◽  
pp. 183-187 ◽  
Author(s):  
Matt M. Kurrek ◽  
Marianne Winkler ◽  
Dwight R. Robinson ◽  
Warren M. Zapol
Keyword(s):  
Pulmonary Hypertension ◽  
Intravenous Administration ◽  
Platelet Factor 4 ◽  
Thromboxane B2 ◽  
Pulmonary Vasculature ◽  
Intravenous Bolus ◽  
Platelet Factor ◽  
Pulmonary Vasoconstriction ◽  
Heparin Anticoagulation ◽  
Protamine 2

Background Reversal of heparin anticoagulation by intravenous protamine sulfate consistently produces acute pulmonary vasoconstriction mediated by the release of thromboxane in the awake lamb. Recently, recombinant platelet factor 4 (rPF4) has been cloned, expressed in Escherichia coli, and infused to reverse heparin anticoagulation in the rat, without producing adverse hemodynamic or pulmonary morphologic effects. The authors sought to learn whether intravenous administration of PF4 is devoid of side effects in the pulmonary circulation of lambs. Methods The authors evaluated the hemodynamic response and plasma release rates of thromboxane during intravenous challenges with heparin-rPF4 (n = 2), rPF-free carrier (n = 5), rPF4 (n = 5), rPF4 after indomethacin (n = 5), protamine (n = 5) and heparin-protamine (n = 5) in 17 awake, hemodynamically monitored lambs. Each lamb underwent up to three random challenges with a 2-h recovery period between each challenge. Results In two lambs, systemic anticoagulation with heparin followed by reversal of anticoagulation with an intravenous bolus of rPF4 (4 mg/kg) led to acute pulmonary vasoconstriction and hypertension with the release of thromboxane (peak pulmonary artery pressure [Ppa] 40 and 33 mmHg and peak plasma thromboxane B2 50 and 30 ng/ml, respectively). Intravenous administration of rPF4 (1.5 mg/kg) alone increased the Ppa from 17.2 +/- 0.7 mmHg (mean +/- SEM) at baseline to 31.2 +/- 2 mmHg at 1 min (n = 5, P < 0.05). This was associated with an increase of plasma thromboxane B2 from 0.06 +/- 0.02 to 3.96 +/- 1.21 ng/ml. Acute pulmonary vasoconstriction lasted approximately 5 min and was completely prevented by pre-treatment with oral indomethacin (10 mg/kg). Intravenous bolus administration of rPF4 carrier (n = 5) or protamine (2 mg/kg) alone (n = 5) did not induce pulmonary hypertension or the release of thromboxane. In five lambs, intravenous heparin (200 U/kg) followed by protamine (2 mg/kg) consistently produced acute pulmonary vasoconstriction and hypertension. Conclusions Intravenous injection of human rPF4 into the awake lamb produces acute pulmonary vasoconstriction and hypertension associated with thromboxane release into circulating blood. The effects of rPF4 on the pulmonary vasculature should be evaluated in primates before rPF4 is substituted for protamine in reversing heparin anticoagulation in humans.

Prostaglandin E2 and thromboxane B2 in cerebrospinal fluid of afebrile and febrile cat

1983 ◽  
Vol 244 (6) ◽  
pp. R785-R793 ◽  
Author(s):  
F. Coceani ◽  
I. Bishai ◽  
C. A. Dinarello ◽  
F. A. Fitzpatrick
Keyword(s):  
Cerebrospinal Fluid ◽  
Prostaglandin E2 ◽  
Intravenous Administration ◽  
Third Ventricle ◽  
Thromboxane A2 ◽  
Thromboxane B2 ◽  
Cisterna Magna ◽  
The Third ◽  
Sequence Of Events ◽  
Pg E2

Levels of prostaglandin (PG) E2 and thromboxane (TX) B2, the stable metabolite of TXA2, were measured by radioimmunoassay in cerebrospinal fluid (CSF) collected from the third ventricle and the cisterna magna of conscious cats. In the absence of fever, PGE2 was usually below the threshold of the assay (0.05-0.37 ng/ml), while TXB2 was measurable in the majority of cases and its concentration was greater in the third ventricle (about 0.7 ng/ml) than in the cisterna magna (about 0.2 ng/ml). At either site, TXB2 content rose if any manipulation was required for the collection of samples. PGE2 levels increased to measurable values (max 1.1-1.4 ng/ml) during fever produced by intrathecal or intravenous administration of leucocytic pyrogen. In contrast, TXB2 concentration rose to an average of 2.2-4 ng/ml only when pyrogen (bacterial or leukocytic) was given intrathecally. Moreover, TXB2 elevation, unlike PGE2 elevation, was limited to the uprise phase of the fever. Imidazole, given either intraperitoneally (50 mg/kg) or intrathecally (3 mg), attenuated the pyrogen fever and suppressed any rise in TXB2 levels. At the same time, the drug tended to increase the PGE2 content of the CSF. Evidence was also obtained suggesting that a fraction of PGE2 is bound to CSF protein, and this event may be important to the inactivation of the compound. These findings are consistent with the concept that PGE2 is involved in the sequence of events underlying pyrogen fever. A role for thromboxane A2 in this process remains to be established.

11-dehydro-thromboxane B2 enzyme immuno assay, a suitable screening assay for aspirin use?

2001 ◽  
Vol 120 (5) ◽  
pp. A596-A596
Author(s):  
M LEERDAM ◽  
F HUDIG ◽  
W ROOIJEN ◽  
E SLAATS ◽  
A GERAEDTS ◽  
...  
Keyword(s):  
Thromboxane B2 ◽  
Screening Assay ◽  
Immuno Assay ◽  
Enzyme Immuno Assay

Intravenous administration of furosemide in heart failure

JAMA ◽  
1967 ◽  
Vol 200 (10) ◽  
pp. 824-829 ◽  
Author(s):  
M. Davidov
Keyword(s):  
Heart Failure ◽  
Intravenous Administration
Sign in / Sign up

Export Citation Format

Share Document